About Takayasu Arteritis
Takayasu Arteritis is a chronic granulomatous vasculitis predominantly affecting the aorta and its major branches, causing transmural inflammation that leads to stenosis, occlusion, or aneurysm formation with resulting limb and organ ischemia. The disease disproportionately affects young women, particularly of Asian descent, and follows a biphasic course with an early inflammatory phase and a later fibrotic obliterative phase in which vascular damage may progress despite suppressed systemic inflammation. Biological therapies targeting IL-6 and TNF have emerged as important steroid-sparing agents in refractory disease.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Takayasu Arteritis trials.
Disease activity assessment using NIH or ITAS criteria is required for most trials; imaging confirmation (MR or CT angiography, PET-CT) of active vessel inflammation is typically mandatory at screening
IL-6 inhibitor trials (tocilizumab) require documented inadequate response to corticosteroids; compile steroid dose history, duration, and relapse pattern
Renal function impairment from renovascular hypertension can affect drug dosing eligibility; provide recent estimated GFR and renal imaging results
Patient Resources
Find recruiting Takayasu Arteritis trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Takayasu Arteritis. Updated daily.